Please login to the form below

Not currently logged in

Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

The results were shared at the European Society for Medical Oncology Congress 2022


Regeneron has announced the presentation of positive data from multiple expansion cohorts of an initial phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo (cemiplimab) in advanced melanoma.

The results, which were shared in a mini-oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, showed the combination treatment demonstrated greater than 60% response rates in two dose expansion cohorts.

"Combining LAG-3 and PD-1 inhibition has shown promise in advanced melanoma but achieving response rates above 50% has been challenging,” Israel Lowy, senior vice president, translational and clinical sciences, oncology at Regeneron said.

The data presented at ESMO was from three dose expansion cohorts in advanced melanoma, including two that enrolled patients who had not previously been treated with a PD-1 or PD-L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced).

The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%. Meanwhile, updated results for one PD-1/PD-L1-naïve cohort demonstrated an ORR of 62.5%, and in a newly presented independent confirmatory cohort, an ORR of 65% was seen.

Adverse events of any grade in the two PD-1/PD-L1-naïve cohorts occurred in 96% of patients, with 29% considered serious.

“Notably, the safety profile for this combination appears in line with Libtayo monotherapy. A phase 3 trial in first-line metastatic melanoma is currently enrolling patients, and we look forward to opening additional trials with this combination in the near future," Lowy added.

The potential use of fianlimab and Libtayo for the treatment of advanced melanoma is investigational, and safety and efficacy of this combination have not been evaluated by any regulatory authority, the company underscored.

Article by
Emily Kimber

13th September 2022

From: Research, Healthcare



Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...